Total Price: $0.00
Contact Information
Recombinant Human PSG3 Protein (His Tag)
SKU: PKSH032925-50
Recombinant Human PSG3 Protein (His Tag)
| SKU # | PKSH032925 |
| Expression Host | HEK293 Cells |
Description
| Synonyms | Carcinoembryonic Antigen SG5, PS-Beta-G-3, PSBG-3., Pregnancy-Specific Glycoprotein 3, Pregnancy-specific beta-1-glycoprotein 3 |
| Species | Human |
| Expression Host | HEK293 Cells |
| Sequence | Gln35-Leu428 |
| Accession | Q16557 |
| Calculated Molecular Weight | 45.2 kDa |
| Observed Molecular Weight | 55-70 kDa |
| Tag | C-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution of 20mM Citrate, 6% Trehalose, 4% Mannitol, 50mM NaCl, 0.05% Tween 80, pH 4.5. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Pregnancy-specific beta-1-glycoprotein 3 is also known as Carcinoembryonic Antigen SG5,Pregnancy-Specific Glycoprotein 3 ,PS-Beta-G-3, PSBG-3.It belongs to the immunoglobulin superfamily. CEA family.It synthesized in large amounts by placental trophoblasts and released into the maternal circulation during pregnancy. Molecular cloning and analysis of several PSG genes has indicated that the PSGs form a subgroup of the carcinoembryonic antigen (CEA) gene family, Members of the CEA family consist of a single N domain, with structural similarity to the immunoglobulin variable domains, followed by a variable number of immunoglobulin constant-like A and/or B domains.